Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
Sung Won LeeJung Hyun KwonHae Lim LeeSun Hong YooHee Chul NamPil Soo SungSoon Woo NamSi Hyun BaeJong Young ChoiSeung Kew YoonNam Ik HanJeong Won JangPublished in: Gut (2019)
This study has demonstrated the clinical outcomes in patients with CHB who received TDF or ETV treatment. There was no difference in the intermediate-term risk of HCC and mortality or LT between the two drugs.